NHLBI/NEI National Institutes of Health
description
Transcript of NHLBI/NEI National Institutes of Health
![Page 1: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/1.jpg)
1
NHLBI/NEI
National Institutes of Health
NHLBI/NEI
National Institutes of Health
![Page 2: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/2.jpg)
2
Diabetes & CVD
• Patients with type 2 diabetes
• 2 to 4 X increased risk of CVD
• Question: What is value of intensive control of CVD risk factors in reducing CVD rates?
• Glycemia• Lipids (HDL-C/TG)• Systolic Blood Pressure
![Page 3: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/3.jpg)
3
Overall Goal for ACCORD
To test three complementary medical
treatment strategies for type 2
diabetes to enhance options for
reducing the very high rate of major
CVD morbidity and mortality
![Page 4: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/4.jpg)
4
The Three Medical Strategies(Three Trials in One)
• Intensive glycemic control• A1C < 6% versus 7.0%-7.9%
• Treatment to increase HDL-C and lower TG (in context of good LDL-C and glycemia control)
• Fenofibrate + Simvastatin versus Simvastatin
• Intensive blood pressure control (in context of good glycemia control)
• SBP < 120 mmHg versus SBP < 140 mmHg
![Page 5: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/5.jpg)
5
Double 2 x 2
IntensiveGlycemicControl
5000
StandardGlycemicControl
5000
Lipid BP
Fibrate Placebo Intensive Std
210021002900 2900
1450 1450
14501450
1050
10501050
1050
10,000
42005800
![Page 6: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/6.jpg)
6
Primary Outcome Measure
First occurrence of a major cardiovascular disease event:
• Nonfatal MI
• Nonfatal Stroke
• Cardiovascular Death
MI’s, Strokes, and Deaths adjudicated by a committee masked to treatment assignment
![Page 7: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/7.jpg)
7
Other ACCORD Outcomes
• Other cardiovascular outcomes
• Total mortality
• Microvascular outcomes
• Health-related Quality of Life (subset)
• Cost-effectiveness (subset)
![Page 8: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/8.jpg)
8
ACCORD Eye Study
National Eye Institute
![Page 9: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/9.jpg)
9
• important primary endpoint• common cause of vision loss• medical management crucial• standard of care: yearly
dilated eye exams
Diabetic Retinopathy
ACCORD Eye Study Rationale
![Page 10: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/10.jpg)
10
• important primary endpoint• DCCT – Primary outcome• UKPDS – Composite primary
outcome
Diabetic Retinopathy
![Page 11: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/11.jpg)
11
Diabetes Control and ComplicationsTrial (DCCT)
Randomized Clinical Trial
Intensive Blood Glucose Controlvs.
Conventional Blood Glucose Control
Type 1 Diabetes
![Page 12: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/12.jpg)
12
0
10
20
30
40
50
60
0 2 4 6 8 10
Primary Intervention - 3 Step Change
Years
PercentWith Event
DCCT Results
ConventionalIntensive
![Page 13: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/13.jpg)
13
0
10
20
30
40
50
60
0 2 4 6 8 10
Secondary Intervention - 3 Step Change
Years
PercentWith Event
DCCT Results
ConventionalIntensive
![Page 14: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/14.jpg)
14
0
0.5
1
1.5
2
2.5
0 1 2
Secondary Intervention - 3 Step Change
Years
PercentWith Event
DCCT Results
P < 0.02
ConventionalIntensive
![Page 15: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/15.jpg)
15
Results of Intensive Therapy:
• Clinically Important Retinopathy (34-76%)
• Photocoagulation (34%)
• First Appearance of Retinopathy (27%)
DCCT Summary
Reduction in Retinopathy
![Page 16: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/16.jpg)
16
Further Retinopathy Progression from the Level at DCCT Closeout
Adjusted For DCCT Closeout Level
02
46
810
1214
1618
20
1 2 3 4
Per
cen
tage
Years of follow-up in EDIC
Conventional RxConventional Rx
Tight Control RxTight Control Rx
![Page 17: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/17.jpg)
17
Randomized Clinical Trial
Intensive Blood Glucose Controlvs.
Conventional Blood Glucose Control
U K Prospective Diabetes Study
Type 2 Diabetes
![Page 18: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/18.jpg)
18
U K Prospective Diabetes StudyMicrovascular Endpoints
10%
30%
20%
6 930 1512
Years
Conventional
Intensive
0%
Event Rate
Photocoagulation/VHRenal Failure/DeathMyocardial Infarction
p=0.0099
![Page 19: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/19.jpg)
19
U K Prospective Diabetes StudyRetinopathy - 2 Step Progression
10%
30%
40%
20%
6 930 12Years
Conventional
Intensive
50%
0%
Event Rate
p=0.78 p=0.02 p=0.01 p=0.01
![Page 20: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/20.jpg)
20
Randomized Clinical Trial
Intensive Blood Pressure Controlvs.
Conventional Blood Pressure Control
U K Prospective Diabetes Study
Type 2 Diabetes
![Page 21: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/21.jpg)
21
U K Prospective Diabetes StudyBlood Pressure by Treatment Group
mm Hg
100
80
120
140
160
3 6 90
Years1 2 4 5 87
Less Tight - Systolic
More Tight - Systolic
Less Tight - Diastolic
More Tight - Diastolic
![Page 22: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/22.jpg)
22
Retinopathy - 2 Step Progression
10%
30%
40%
20%
6 930 12
Years
Less Tight BP Control
More Tight BP Control
50%
0%
Event Rate
UKPDS Blood Pressure Trial
P=0.38 P=0.02 P=0.004
![Page 23: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/23.jpg)
23
Serum Cholesterol
Diabetic Retinopathy
and
![Page 24: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/24.jpg)
24
Early Treatment Diabetic
Retinopathy Study (ETDRS)
Wisconsin Epidemiologic Study of
Diabetic Retinopathy (WESDR)
Serum cholesterol
Observational Data
![Page 25: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/25.jpg)
25
Doubled the risk of retinal hard
50% increased risk of moderate vision
50% increased risk of developing hard exudate at baseline
Serum cholesterol-ETDRS Results
Elevated levels:
exudate during follow-up
loss at 5 years
![Page 26: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/26.jpg)
26
to assess the rates of progression of
medical treatment on diabetic retinopathy
To evaluate the effects of these 3
diabetic retinopathy
ACCORD Eye Study
Objectives
![Page 27: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/27.jpg)
27
Baseline (within 4 months of enrollment)
Sample size: n=4,065
4 years for all enrolled at baseline
ACCORD Eye Study
Eye Exam and Fundus Photos
![Page 28: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/28.jpg)
28
Clinical coordinator from the diabetes
Coordinating Center (Wake Forest U.) and
Eye exam form, fundus photographs sent to
clinic will schedule patient
ACCORD Eye Study
Study flow
Reading Center (U. of Wisconsin)
![Page 29: NHLBI/NEI National Institutes of Health](https://reader036.fdocuments.net/reader036/viewer/2022062305/56814f0a550346895dbc9d81/html5/thumbnails/29.jpg)
29Alexandria meeting
Feb 18-20, 2004